Want to see TEM full AI Analyst Report?
TEM Stock Chart & Stats
$55.87
-$0.17(-0.45%)
At close: 4:00 PM EST
$55.87
-$0.17(-0.45%)
Day’s Range― - ―
52-Week Range$41.73 - $104.32
Previous CloseN/A
Volume1.41M
Average Volume (3M)7.21M
Market Cap
$10.08B
Enterprise Value$9.31B
Total Cash (Recent Filing)$639.07M
Total Debt (Recent Filing)$1.32B
Price to Earnings (P/E)―
Beta3.01
Next Earnings
Aug 06, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.71
Shares Outstanding174,520,980
10 Day Avg. Volume7,001,504
30 Day Avg. Volume7,205,304
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)20.94
Price to Sales (P/S)8.09
P/FCF Ratio-43.03
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue6.83
Enterprise Value/Gross Profit9.81
Enterprise Value/Ebitda-68.67
Forecast
1Y Price Target
$65.93Price Target Upside18.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
EPS Forecast (FY)-0.36
Revenue Forecast (FY)$1.59B
Bulls Say, Bears Say
Bulls Say
Revenue Scale & GrowthSustained double‑digit top‑line growth and an upgraded full‑year guide reflect expanding demand for both diagnostics and life‑sciences services. That scale increases recurring revenue visibility, supports longer sales cycles with pharma partners and underpins investments in product and commercial capability over the next 2–6 months.
Proprietary Data & PlatformA >500PB proprietary clinico‑molecular dataset plus GPU model‑building creates a durable competitive advantage: it enables differentiated AI products, sticky licensing relationships and higher switching costs for pharma and health‑system customers, supporting long‑term monetization of analytics and models.
Large Pharma Collaborations & BookingsSignificant strategic agreements and repeated >$100M bookings provide multi‑year revenue visibility and validate Tempus’s data/services moat. Large pharma commitments tend to be sticky, drive recurring licensing and services demand, and support margin improvement as fixed platform costs scale with contracted revenue.
Bears Say
Negative Cash GenerationPersistent negative operating and free cash flow means the business is not yet self‑funding; this increases reliance on external financing to cover growth investments and working capital. Over a multi‑quarter horizon, continued cash burn constrains strategic flexibility and raises refinancing risk if profitability lags.
Elevated LeverageMaterial absolute debt and leverage limit balance‑sheet optionality while losses persist. Even with recent liability management, elevated debt raises interest and covenant risk, reduces capacity for opportunistic M&A or R&D spend, and heightens vulnerability to cash‑flow volatility over the coming quarters.
Ongoing Operating LossesDespite gross margin expansion, persistent operating and net losses indicate the company has not converted core profitability improvements into sustained positive operating income. Continued negative margins can impede reinvestment, delay self‑funding and require repeated financing until adjusted EBITDA and cash‑flow sustainably turn positive.
Tempus AI, Inc. Class A News
TEM FAQ
What was Tempus AI, Inc. Class A’s price range in the past 12 months?
Tempus AI, Inc. Class A lowest stock price was $41.73 and its highest was $104.32 in the past 12 months.
What is Tempus AI, Inc. Class A’s market cap?
Tempus AI, Inc. Class A’s market cap is $10.08B.
When is Tempus AI, Inc. Class A’s upcoming earnings report date?
Tempus AI, Inc. Class A’s upcoming earnings report date is Aug 06, 2026 which is in 37 days.
How were Tempus AI, Inc. Class A’s earnings last quarter?
Tempus AI, Inc. Class A released its earnings results on May 05, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.2 by $0.07.
Is Tempus AI, Inc. Class A overvalued?
According to Wall Street analysts Tempus AI, Inc. Class A’s price is currently Undervalued.
Does Tempus AI, Inc. Class A pay dividends?
Tempus AI, Inc. Class A does not currently pay dividends.
What is Tempus AI, Inc. Class A’s EPS estimate?
Tempus AI, Inc. Class A’s EPS estimate is -0.15.
How many shares outstanding does Tempus AI, Inc. Class A have?
Tempus AI, Inc. Class A has 174,520,980 shares outstanding.
What happened to Tempus AI, Inc. Class A’s price movement after its last earnings report?
Tempus AI, Inc. Class A reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.2. Following the earnings report the stock price went down -1.054%.
Which hedge fund is a major shareholder of Tempus AI, Inc. Class A?
Currently, no hedge funds are holding shares in TEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tempus AI, Inc. Class A Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$65.93 (18.00% Upside)
$65.93 (18.00% Upside)
Blogger Sentiment
Bullish
TEM Sentiment 88%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days >0.1%
Last 30 Days ▲ 3.6%
Last 30 Days ▲ 3.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.34%
12-Months-Change
Fundamentals
Return on Equity
-70.24%
Trailing 12-Months
Asset Growth
38.36%
Trailing 12-Months
Company Description
Tempus AI, Inc. Class A
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
TEM Company Deck
TEM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong topline momentum and durable demand in both diagnostics and data/applications: revenue growth (~36% YoY), robust Data & Insights growth (40.5% YoY; Insights >44%), expansion of large pharma collaborations (Merck, Gilead), rising bookings/TCV and an upgraded full-year revenue guide to $1.59B–$1.60B with adjusted EBITDA targeted at ~$65M. Key risks and near-term headwinds include Q1 cash-flow timing effects, slower hereditary volumes early in the year, MRD reimbursement and scaling constraints, and some regulatory timing uncertainty. Overall the positives (strong growth, expanding high-value contracts, improving EBITDA trajectory and sizable data assets) outweigh the transitory operational and reimbursement challenges.View all TEM earnings summariesTEM Stock 12 Month Forecast
Average Price Target
$65.93
▲(18.00% Upside)
Technical Analysis
Ownership Overview
22.56% Insiders
8.88% Mutual Funds
30.20% Other Institutional Investors
22.52% Public Companies and Individual Investors